GlassScriptPhysician profile
Clifton L Cox
NPI 1811956899
$3,907.09
in general payments reported to CMS, 2019-2025
26 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $69.99 · 2021: $445 · 2022: $1,555 · 2023: $131 · 2024: $554 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397 · Education: $13.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.51 |
| Education | $13.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,550.26 | 2022-2025 | Eohilia, Entyvio, Gattex |
| Abbvie INC. | $485.40 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $453.34 | 2019-2024 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $244.01 | 2019-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $192.84 | 2024-2025 | Voquezna |
| Ethicon US, LLC | $114.86 | 2021 | |
| Janssen Biotech, INC. | $111.67 | 2019-2025 | Tremfya, Stelara |
| Braintree Laboratories, INC. | $106.35 | 2021-2025 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $78.82 | 2019-2025 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $78.59 | 2024-2025 | Iqirvo, Bylvay |
| Pfizer INC. | $62.22 | 2023 | |
| Ardelyx, INC. | $60.33 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $59.20 | 2019-2024 | |
| Amgen INC. | $52.85 | 2022-2023 | Avsola, Amjevita |
| Lilly USA, LLC | $42.09 | 2023-2024 | Omvoh |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $31.79 | 2025 | Rezdiffra |
| Evoke Pharma, INC. | $30.61 | 2025 | |
| Organon LLC | $30.06 | 2022-2024 | |
| Celltrion USA INC. | $27.59 | 2024-2025 | Vegzelma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $25.81 | 2025 | Dupixent |
| Ucb, INC. | $16.28 | 2019 | |
| Aimmune Therapeutics, INC. | $16.09 | 2025 | Vowst |
| Medtronic, INC. | $12.62 | 2021 | |
| Redhill Biopharma INC. | $12.34 | 2022 | |
| Stryker Corporation | $11.07 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,805.23 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifton Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.